Exact Sciences Corp. (Nasdaq: EXAS) announced preliminary fourth quarter revenue that more than doubled over last year. Shares of the molecular diagnostics company soared $2.88 to close at $17.98.
Exact Sciences reports strong preliminary revenue
January 09, 2017 at 19:28 PM EST
